AbbVie Inc. (ABBV)

AbbVie Financials Overview

Financials in millions USD. Fiscal year is January - December.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue Revenue Growth	64,386	61,160	56,334	54,318	58,054	56,197
Revenue Growth	10.39%	8.57%	3.71%	-6.44%	3.30%	22.69%
Gross Profit Gross Profit Growth	46,868	43,803	39,645	37,492	41,527	38,883
Operating Income Operating Income Growth	22,894	21,115	17,422	18,214	20,228	19,759
Net Income Net Income Growth	6,270	4,186	4,238	4,820	11,782	11,468
Earnings Per Share EPS Growth	3.54	2.36	2.39	2.72	6.63	6.45
EPS Growth	68.54%	-1.26%	-12.13%	-58.97%	2.79%	137.13%

Revenue by Segment

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Immunology Immunology Growth	32,587	30,406	26,682	26,136	28,924	25,284
Neuroscience Neuroscience Growth	11,905	10,767	8,999	7,717	6,528	5,927
Oncology Oncology Growth	6,627	6,655	6,555	5,915	6,577	7,228
Aesthetics Aesthetics Growth	4,947	4,860	5,176	5,294	5,333	5,233
Eye Care Eye Care Growth	-	2,109	2,242	2,415	2,701	3,567
Other Key Products Other Key Products Growth	3,820	3,736	3,648	3,806	3,854	5,489
All Other All Other Growth	3,411	2,627	3,032	3,035	4,137	2,673
Revenue (Total) Revenue (Total) Growth	64,386	61,160	56,334	54,318	58,054	56,197

Cash & Debt

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Investments Cash & Investments Growth	6,569	5,257	5,555	12,816	9,229	9,830
Total Debt Total Debt Growth	70,885	68,400	68,250	60,579	64,583	77,597
Net Cash (Debt) Net Cash Growth	-64,316	-63,143	-62,695	-47,763	-55,354	-67,767
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share Net Cash Per Share Growth	-36.27	-35.61	-35.36	-26.94	-31.13	-38.14

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Operating Cash Flow Operating Cash Flow Growth	19,507	19,030	18,806	22,839	24,943	22,777
Capital Expenditures CapEx Growth	-1,297	-1,214	-974	-777	-695	-787
Free Cash Flow Free Cash Flow Growth	18,210	17,816	17,832	22,062	24,248	21,990
Free Cash Flow Growth	-0.16%	-0.09%	-19.17%	-9.01%	10.27%	30.97%

Margins

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Gross Margin	72.79%	71.62%	70.38%	69.02%	71.53%	69.19%
Operating Margin	35.56%	34.52%	30.93%	33.53%	34.84%	35.16%
Pretax Margin	13.51%	10.79%	6.60%	11.51%	23.21%	23.11%
Profit Margin	9.74%	6.84%	7.52%	8.87%	20.29%	20.41%
FCF Margin	28.28%	29.13%	31.65%	40.62%	41.77%	39.13%

Dividends

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug 19, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Dividend Per Share Dividend Per Share Growth	6.920	6.650	6.290	5.990	5.710	5.310
Dividend Per Share Growth	5.56%	5.72%	5.01%	4.90%	7.53%	9.71%
Dividend Yield	2.67%	2.98%	3.75%	4.25%	4.04%	4.66%

Valuation

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug 19, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
PE Ratio	73.15	96.47	74.10	56.77	24.25	20.87
Forward PE	17.06	16.57	14.81	13.96	12.72	10.04
P/FCF Ratio	25.13	22.67	17.61	12.40	11.78	10.89
PS Ratio	7.11	6.60	5.57	5.04	4.92	4.26

Data Sources: S&P Global Market Intelligence and Fiscal.ai Last updated: Jul 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company. Revenue segment data is provided by Fiscal.ai.

Update frequency:

Quarterly

Last checked:

Aug 19, 2026

Data Sources Report a data error